Omalizumab (Xolair)

Provider Order Form rev. 3/13/24



PATIENT INFORMATION	ON	Re	ferral Sta	t us: 🗆 New Referra	l □ Updated	l Order □ Order Renewal
Date: Patient Name:					DOE	3:
ICD-10 code (required):	☐ J45.50 (severe persistent	asthma, uncom	plicated)	□ L50.8 (Chronic	urticaria)	□ Other
If Other, give ICD-10 descr	ription:					
□ NKDA Allergies:				W	eight (lbs/kg):	Height:
Patient Status: ☐ New to Therapy ☐ Continuing Therapy			Last Trea	tment Date:	Nex	t Due Date:
PROVIDER INFORMAT	ION					
Referral Coordinator Name:			Referral Coordinator Email:			
Ordering Provider:			Provider NPI:			
Referring Practice Name:			Phone:		Fax:	
Practice Address:			City:		State:	Zip Code:
NURSING Serum IgE level and date resulted (results) Provide nursing care per IVX Nursing Procedures, including reaction management and post-procedure observation NOTE: IVX Adverse Reaction Management Protocol available for review at www.ivxhealth.com/forms (version 05.01.2023) SPECIAL INSTRUCTIONS		✓ Om Ref (if r OBSER) Pati Pati Pati	APY ADMINISTRATION malizumab (Xolair) Dose: □ 75mg □ 150mg □ 225mg □ 300mg □ 375mg □ 450mg □ 525mg □ 600mg Route: subcutaneous injection Frequency: □ every 2 weeks □ every 4 weeks / □ other: □ other: □ efills: □ Zero / □ for 12 months / □ □ efills: □ Zero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Efills: □ Tero / □ for 12 months / □ □ efills: □ Tero / □ for 12 months / □ □ efills: □ Efills: □ Tero / □ for 12 months / □ □ efills: □ Ef			
Determine dose (mg) and dosing frequency by serum total IgE level (IU/mL) measured before the start of treatment, and by body weight (kg). Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after XOLAIR administration. Provider Name (Print) Provider Signature Date						
FAX NUMBERS □ AUSTIN: 512-772-2824 □ BAY AREA: 844-889-0275 □ CHARLOTTE: 336-663-0143 □ CHICAGO: 312-253-7244 □ CINCINNATI: 844-946-0868 □ COLUMBUS: 844-627-2675	☐ CONNECTICUT: 860-955-1532 ☐ DAYTONA: 386-259-6096 ☐ DELAWARE: 302-596-8553 ☐ EAST TN: 615-425-7427 ☐ FT. LAUDERDALE: 754-946-2052 ☐ HARRISBURG: 844-859-4235 ☐ HOUSTON: 832-631-9595	☐ INDIANAPOLI: ☐ JACKSONVILLI ☐ KANSAS CITY: ☐ LAKELAND: 86 ☐ LITTLE ROCK: ☐ MIAMI: 786-74 ☐ MIDDLE TN: 88	E: 904-212-23 844-900-129 53-316-3910 501-451-564 14-5687	2 NORTHWEST AR:	51-227-2823 888-615-1445 16-0867 -768-9044 44-820-9641	☐ RALEIGH: 919-287-2551 ☐ SAN ANTONIO: 726-238-9950 ☐ SARASOTA: 941-870-6550 ☐ SOUTH JERSEY: 856-519-5309 ☐ SOUTHWEST FL: 813-283-9144 ☐ TAMPA: 844-946-0849 ☐ WEST TN: 888-615-1445